pimodivir

Pimodivir (VX-787) 是一种通过口服的甲型流感病毒聚合酶抑制剂，与病毒 PB2 亚基相互作用。

Pimodivir is an inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. The cell-based EC50 for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay. VX-787 is active against a diverse

Pimodivir, also known as VX-787, JNJ-872, is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. VX-787 binds the cap-binding domain of the PB2 subunit with a KD (dissociation constant) of 24 nM as determined by isothermal titration calorimetry (ITC). The cell-based EC50 (the concentration of compound that ensures 50% cell viability of an uninfected control) for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay, with a similar EC50 in a viral RNA replication assay. VX-787 is active against a diverse panel of influenza A virus strains, including H1N1pdm09 and H5N1 strains, as well as strains with reduced susceptibility to neuraminidase inhibitors (NAIs).

Clorgyline(氯吉灵)是一种不可逆和选择性的MAO-A抑制剂，具有口服活性和血脑屏障透过性的优点，通过形成中间自由基阳离子使酶的结构改变，具有抗抑郁作用，可以降低1% fbs刺激的VSMC（血管平滑肌细胞）生长。